# Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations

> **NCT03839342** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 26 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Binimetinib
- **DRUG:** Encorafenib

## Key facts

- **NCT ID:** NCT03839342
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-07
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03839342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03839342, "Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03839342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*